Co-Diagnostics, Inc. (NASDAQ: CODX), is a molecular diagnostics company that intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It also intends to sell diagnostic equipment from other manufacturers as self-contained lab systems.
It’s been almost a year since CODX completed its IPO raising $7 million with an offering of 1.2 million shares at $6 a share. In late February 2018 the company shares hit their 2018 low of $1.45 per share.
On Friday, June 1, 2018, CODX shares closed at $4.79 (+65.17%) on unusually high volume of 20.9 million shares traded.
Recent Events
June 1, 2018. Co-Diagnostics announced that the Company’s CoPrimer™ technology is being employed to achieve the objectives of a research project conducted by the Wang Group at Stanford University. The purpose of the study is to develop more efficient methods to detect multiple genetic mutations in the EGFR (epidermal growth factor receptor) gene, including the most frequently occurring mutations in lung cancer, within a single reaction. https://finance.yahoo.com/news/co-diagnostics-inc-announces-participation-103000825.html
Products
Co-Diagnostics’ CoDx™ portfolio of molecular diagnostics development products and tests represent a radical new advancement in the understanding of the molecular interactions of DNA. Leading a global health revolution through mathematical innovations, cost reductions, and wider margins with our shareholders in mind,
- using highly specialized, proprietary cooperative-theory mathematics,
- leading to a revolutionary leap forward in the detection of infectious diseases, genetic disorders and other conditions,
- at a fraction of the cost of other DNA-based tests,
- designed for a new generation of affordable, mobile point-of-care diagnostic devices, and compatible with many other existing, commercially-available devices,
- making state-of-the-art diagnostics available anywhere in the world, including developing countries.
CoPrimers™ are sixth-generation probes for real-time PCR and are the latest innovation from Dr. Brent Satterfield and Co-Diagnostics, providing the most potent and advanced reagents available today. CoPrimers™ enhance the speed, accuracy and cost effectiveness of PCR. CoPrimers™ virtually eliminate the formation of primer dimers, a bane to test designers, which occur when errors are amplified during the PCR process, causing false positives and negatives. CoPrimers™ are most effective at eliminating primer dimers when running multiple PCR tests simultaneously (multiplexing).
RapidProbe™ is a fifth- generation mathematically-engineered probe design for real-time PCR. It increases probe accuracy while reducing design complexity and expense. RapidProbe™ is faster than fourth generation Tentacle Probes™ and far less expensive and up to 200 times faster than hairpin probes. Highly sensitive, RapidProbe™ can detect even a single virus in a DNA sample. Brighter probes translate to higher accuracy and lower-cost detection equipment. RapidProbe™ brings the quencher and flourophore into close proximity. When the probe initiates hybridization, it “unzips,” creating a brighter signal than standard probes.
HotStaRT™ – Reduces false readings in real-time PCR. HotStaRT™ is a unique hot start for PCR and is the first to work on both RNA and DNA reactions, reducing both false positives and negatives. HotStaRT™ adds proprietary chemical “hooks” to an oligonucleotide, causing them to stick to the binding site at low temperatures, reducing non-specific reactions. HotStaRT™ works on both polymerase and reverse transcriptase reactions. The charts below illustrate its effectiveness at improving sensitivity and outcomes on the reverse transcriptase reaction.
About
Co-Diagnostics, Inc., a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It also intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. Co-Diagnostics, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.
Working in tandem, both affordable tests, and affordable diagnostic devices will revolutionize DNA diagnostics, for the first time making accurate detection of genetic disorders and infectious diseases far less expensive and much more broadly available. This is made possible by combining proprietary software, patented reagent technologies and an array of affordable, accurate PCR tests.
Dr. Brent Satterfield invented the Company’s suite of intellectual properties. CODX scientists were the first to understand the complex mathematics of DNA test design, to “engineer” a DNA test and to automate algorithms that rapidly screen millions of possible options to pinpoint the optimum design. This bio-engineering approach to DNA test development is unique to Co-Diagnostics and is based on “cooperative theory,” a new generation of mathematical analytics created by Dr. Satterfield.
CDI’s diagnostics systems enable very rapid, low-cost, sophisticated molecular testing for organisms and genetic diseases by greatly automating historically complex procedures in both the development and administration of tests. CDI’s newest technical advance involves a novel approach to PCR primer design (cooperative primers) that eliminates one of the key vexing issues of PCR amplification, the exponential growth of primer-dimer pairs which adversely interferes with identification of the target DNA. In addition, CDI scientists have enhanced the understanding of the mathematics of DNA test design, so as to “engineer” a DNA test and automate algorithms to screen millions of possible designs to find the optimum DNA test design. CDI’s proprietary platform of Co-Dx™ technologies integrates and streamlines these steps as it analyzes biological samples.
Co-Diagnostics’ CoDx™ portfolio of molecular diagnostics development products and tests represent a radical new advancement in the understanding of the molecular interactions of DNA. The Company uses highly specialized, proprietary cooperative-theory mathematics, leading to a revolutionary leap forward in the detection of infectious diseases, genetic disorders and other conditions. CoDx™ tests are a fraction of the cost of other DNA-based tests, designed for a new generation of affordable, mobile point-of-care diagnostic devices and compatible with many other devices, making state-of-the-art diagnostics available anywhere in the world, including developing countries.
Financial review FYE 2017 and Q1 2018
Revenue for the year totaled $7,700, primarily licensing revenue, compared to zero revenue in full year 2016.
Deferred income at December 31, 2017, amounted to $184,000; this is revenue that will be recognized in future quarters.
The Company ended the year with cash and equivalents of $3.5 million and zero long-term debt.
The Company reported a net loss for full year 2017 of approximately $7.0 million, or $0.63 per fully diluted share. This included a non-cash loss of $2,072,000 that was recognized when noteholders converted debt to stock in the IPO, and $2,033,000 of non-cash expenses related to the issuance of stock for services.
Q1 2018 financial review
For the three months ended March 31, 2018 we generated $9,696 of revenues compared to no revenues in the three months ended March 31, 2017.
For the three months ended March 31, 2018 and for the three months ended March 31, 2017, they recorded no costs of revenues.
Operating expenses were $1,287,127 for the three months ended March 31, 2018 compared to total operating expenses of $564,365 for the three months ended March 31, 2017.
Research and development expenses increased by $31,727 from $265,688 for the three months ended March 31, 2017 to $297,415 for the three months ended March 31, 2018.
Net loss for the three months ended March 31, 2018 of $1,310,233 compared with a net loss for the three months ended March 31, 2017 of $705,742.
At March 31, 2018, they had cash and cash equivalents of $2,541,242.
Stock influences and risk factors
If the potential market for the CODX products grows substantially, it could act as a catalyst for the company’s shares;
The company may require additional funding to operate and develop products and that financing could be dilutive;
The biotech industry carries inherent risks such as regulatory restrictions and intense competition;
The company has produced limited revenues and only net losses and there is no guarantee they ever will be profitable.
Stock chart
On Friday, June 1, 2018, CODX shares closed at $4.79 (+65.17%) on unusually high volume of 20.9 million shares traded. The current RSI (14) is 80.11
At $4.79, CODX shares are trading above their 50 DMA and 200 DMA of $2.08 and $3.68 respectively.
Disclaimer
Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
Traders News Source has not been compensated for this report by anyone and the opinions if any are that of the author Vikas Agrawal, CFA. Author’s Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I, wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in the article.
This web site, published by TNS LLC, and is an investment newsletter that is built on the premise of assisting individual investors in learning about investing. Our goal as publishers of financial information is to provide research and analysis of investments to our subscribers. TNS LLC does not give buy or sell recommendations. We do purchase distribution rights from analyst, financial writers and bloggers for a fee that may be licensed to issue price targets and recommendations. Furthermore, we encourage you to speak to a licensed professional prior to making an investment in any type of publicly traded security.
We do sell advertising to other companies including brokerage firms, web sites, publicly traded issuers, investor relations firms, and investment publications, among others. TNS LLC makes no warranty as to the policies of these organizations, and in no way endorses their offers, services, or the content of their advertisements.
When an advertiser is a publicly traded company or a third party acting on behalf of a public company, we fully disclose all compensation in the email advertisement. Such disclosure is included in a disclosure statement in each of the advertisements sent via email.
17B Disclosure
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.
PLEASE NOTE WELL: TNS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operator’s owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D.
TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur.
Understand there is no guarantee past performance will be indicative of future results. In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.
